The FDA is Developing, Approving, and Expediting Exciting New Therapies
source: pixabay.com

The FDA is Developing, Approving, and Expediting Exciting New Therapies

  Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research (CDER) recently gave an interview to the publication FDA Voices about the agency’s approval in 2019 of a…

Continue Reading The FDA is Developing, Approving, and Expediting Exciting New Therapies
Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients
source: pixabay.com

Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients

A New Working Group A team of healthcare professionals from the Institute for Quality and Efficacy in Health Care, the Drug Commission of the German Medical Association, and the Charité…

Continue Reading Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients
Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU
LhcCoutinho / Pixabay

Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

According to a story from BioSpace, Chugai Pharmaceutical Co., Ltd. has recently announced that the Marketing Authorisation Application for the its drug satralizumab has been accepted by the European Medicines…

Continue Reading Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show

According to a story from Biotech 365, the biotechnology company Viela Bio announced the publication of critical results from a recent study that tested the company's investigational drug inebilizumab as…

Continue Reading An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show
FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

According to a publication at Markets Insider, the Food and Drug Administration (FDA) recently approved Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder. The approval marks the first…

Continue Reading FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation

According to a story from BioSpace, the biotechnology company Viela Bio recently announced that the US Food and Drug Administration (FDA) has awarded an experimental therapy in development by the…

Continue Reading Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation
Clinical Trial Suggests Soliris Could be an Effective Treatment for Neuromyelitis Optica Spectrum Disorders
qimono / Pixabay

Clinical Trial Suggests Soliris Could be an Effective Treatment for Neuromyelitis Optica Spectrum Disorders

According to a story from BusinessWire, the drug developer Alexion Pharmaceuticals, Inc., recently announced positive results for its Phase 3 trial testing Soliris as a therapy for neuromyelitis optica spectrum…

Continue Reading Clinical Trial Suggests Soliris Could be an Effective Treatment for Neuromyelitis Optica Spectrum Disorders
Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica
LionFive / Pixabay

Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica

According to a story from Newswise, a team of scientists and researchers have recently completed research that managed to reveal the genetic nature of the unusual rare disease neuromyelitis optica.…

Continue Reading Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica
A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica
source: pixabay.com

A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica

According to an article from brightsurf.com, a commonly used allergy medication called cetirizine (commonly marketed under the name Zyrtec) was able to prevent relapse in patients with neuromyelitis optica in…

Continue Reading A Widely Popular Allergy Medication Could Prevent Relapse in Neuromyelitis Optica